Machado C M, Boas L S Vilas, Mendes A V A, Santos M F M, da Rocha I F, Sturaro D, Dulley F L, Pannuti C S
Virology Laboratory (LIM 52-HCFMUSP) of Instituto de Medicina Tropical de São Paulo, Brazil.
Bone Marrow Transplant. 2003 Apr;31(8):695-700. doi: 10.1038/sj.bmt.1703900.
Respiratory viruses (RVs) frequently cause severe respiratory disease in bone marrrow transplant (BMT) recipients. To evaluate the frequency of RV, nasal washes were collected year-round from BMT recipients with symptoms of upper respiratory tract infection (URI). Direct immunofluorescence assay was performed for respiratory syncytial virus (RSV), influenza (Flu) A and B, adenovirus and parainfluenza (Paraflu) virus. Patients with RSV pneumonia or with upper RSV infection, but considered at high risk for developing RSV pneumonia received aerosolized ribavirin. Oseltamivir was given to patients with influenza. A total of 179 patients had 392 episodes of URI. In all, 68 (38%) tested positive: RSV was detected in 18 patients (26.4%), Flu B in 17 (25%), Flu A in 11 (16.2%) and Paraflu in 7 (10.3%). A total of 14 patients (20.6%) had multiple RV infections or coinfection. RSV pneumonia developed in 55.5% of the patients with RSV-URI. One of the 15 patients (6.6%) with RSV pneumonia died. Influenza pneumonia was diagnosed in three patients (7.3%). RSV and influenza infections peaked in fall-winter and winter-spring months, respectively. We observed decreased rates of influenza and parainfluenza pneumonia and low mortality because of RSV pneumonia. The role of antiviral interventions such as aerosolized ribavirin and new neuraminidase inhibitors remains to be defined in randomized trials.
呼吸道病毒(RVs)经常在骨髓移植(BMT)受者中引起严重的呼吸道疾病。为了评估RVs的感染频率,全年收集有上呼吸道感染(URI)症状的BMT受者的鼻腔灌洗液。对呼吸道合胞病毒(RSV)、甲型和乙型流感病毒(Flu)、腺病毒和副流感病毒(Paraflu)进行直接免疫荧光检测。患有RSV肺炎或上呼吸道RSV感染但被认为有发展为RSV肺炎高风险的患者接受雾化利巴韦林治疗。对流感患者给予奥司他韦。共有179例患者发生了392次URI发作。其中,68例(38%)检测呈阳性:18例(26.4%)检测到RSV,17例(25%)检测到乙型流感病毒,11例(16.2%)检测到甲型流感病毒,7例(10.3%)检测到副流感病毒。共有14例患者(20.6%)发生了多种RV感染或合并感染。55.5%的RSV-URI患者发生了RSV肺炎。15例RSV肺炎患者中有1例(6.6%)死亡。3例患者(7.3%)被诊断为流感肺炎。RSV和流感感染分别在秋冬和冬春季节达到高峰。我们观察到流感和副流感肺炎的发生率下降,且RSV肺炎导致的死亡率较低。雾化利巴韦林和新型神经氨酸酶抑制剂等抗病毒干预措施的作用仍有待在随机试验中确定。